Deke Medtech

Hangzhou Deke Medtech Co., Ltd. was registered and established in 2017 in the Binjiang District of Hangzhou City. Incubated by Hangzhou Denuo Medtech, the company is committed to becoming the world's first innovative leading enterprise to apply hydrogel myocardial repair technology in the clinical treatment of heart failure.Heart failure, as the end-stage manifestation of cardiovascular diseases such as hypertension and coronary heart disease, has a high incidence and mortality rate. Traditional treatment options involve medication to alleviate symptoms, but the five-year mortality rate for heart failure patients remains as high as 50%. Current non-drug treatments for end-stage heart failure include cardiac resynchronization therapy (CRT), left ventricular assist devices (LVAD), and heart transplantation, but these options come with issues such as high costs, complex surgeries, and monopolization of technology by foreign countries. Deke Medtech’s hydrogel technology adopts an innovative approach of using implantable materials for myocardial repair, a world-first initiative that will bring new hope to China’s 4.5 million heart failure patients.